Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M33.3Revenue (TTM) $M--Net Margin (%)--Altman Z-Score--
Enterprise Value $M-1.2EPS (TTM) $-2.0Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.7ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NVLS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NVLS is held by these investors:



NVLS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rodman David MalcomExec Vice President and CMO 2017-01-04Sell6,687$2.2715.86view
Carruthers R MichaelExec Vice President / CFO 2016-12-02Buy24,000$2.0925.84view
Rodman David MalcomExec Vice President and CMO 2016-10-04Sell5,820$7.96-66.96view
Rodman David MalcomExec Vice President and CMO 2016-07-05Sell5,950$4.66-43.56view
Congleton JonPresident and CEO 2016-06-16Buy5,000$3.87-32.04view
Congleton JonPresident and CEO 2016-03-24Buy5,000$4.22-37.68view
Congleton JonPresident and CEO 2016-03-22Buy5,000$4.38-39.95view
Congleton JonPresident and CEO 2015-12-11Buy5,000$8.1-67.53view
CONWAY ROBERT EDirector 2015-12-09Buy10,000$8.1-67.53view
Flynn James E 2015-06-23Buy250,000$14-81.21view

Quarterly/Annual Reports about NVLS:

News about nvls:

Articles On GuruFocus.com
No related article found.

More From Other Websites
NIVALIS THERAPEUTICS, INC. Financials Feb 17 2017
Nivalis Therapeutics reports 4Q loss Feb 14 2017
Nivalis Therapeutics reports 4Q loss Feb 14 2017
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 13 2017
Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2016 Financial Results Feb 13 2017
BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda Jan 19 2017
Here’s What Happens Now At Nivalis Therapeutics Inc (NVLS) Jan 16 2017
Nivalis to lay off CEO and 80% of staff as part of restructuring Jan 12 2017
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Jan 12 2017
Nivalis Therapeutics Announces Corporate Restructuring Jan 12 2017
Colorado biotech to streamline operations, explore alternatives after clinical trial failure Jan 04 2017
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 04 2017
Nivalis Therapeutics Announces Review of Strategic Alternatives Jan 03 2017
Nivalis Therapeutics Announces Review of Strategic Alternatives Jan 03 2017
New Strong Buy Stocks for December 30th Dec 30 2016
These 5 Stocks Under $10 Could Make You a Lot of Money Dec 22 2016
How Achaogen Inc (AKAO) Stacks Up Against Its Peers Dec 19 2016
Should You Buy Nivalis Therapeutics Inc (NVLS)? Dec 07 2016
6 Companies That Destroyed Shareholders Last Week Dec 03 2016
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda Dec 02 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)